EXOZYMES INC.
EXOZNasdaq
$6.02
↓ -3.2%Jul 17 close · end-of-day
Price
1Y↓ -36.6%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$50.9M
Enterprise Value
$49.5M
P/E
—
P/S
—
P/B
33.3
EV/EBITDA
—
PEG
—
FCF Yield
-13.9%
Dividend Yield
—
Revenue (TTM)
—
Net Income (TTM)
-$9.7M
Free Cash Flow (TTM)
-$7.1M
Gross Margin
—
Operating Margin
—
Net Margin
—
ROE
-633.0%
ROIC
-9601.2%
Debt / Equity
—
Net Cash
$1.4M
Return 1Y
-34.9%
Company profile
eXoZymes, Inc. operates as a synthetic biochemical company in the United States. The company develops SimplePath, a platform that produces chemicals, including pharmaceuticals, fuels, materials, food additives, and novel compounds. Its platform also comprises one or more module which consist of one or more enzymes that work together to perform a defined biocatalytic conversion. The company was formerly known as Invizyne Technologies, Inc. and changed its name to eXoZymes, Inc. in February 2025. The company was founded in 2014 and is headquartered in Monrovia, California.
- CEO
- Michael Heltzen
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Employees
- 29
- Headquarters
- California
- Website
- exozymes.com
Management & directors
- Korman Tyler PazChief Scientific Officer
- Nawaz FouadVice President- Finance
- Opgenorth Paul HideoVice President, Development
- Perriman Damien AlanChief Commercial Officer
- Heltzen MichaelChief Executive Officer
Roles derived from SEC Form 4 filings.
Earnings
EXOZ Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue——
Diluted EPS-$0.28↑ +27.3%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Revenue | $70,069.00 | — | — |
| Gross profit | — | — | — |
| Operating income | -$1.8M | -$5.9M | -$9.7M |
| Net income | -$2.0M | -$5.9M | -$9.2M |
| Diluted EPS | -$0.33 | -$0.89 | -$1.09 |
| Operating cash flow | -$1.2M | -$8.5M | -$6.5M |
| Free cash flow | -$1.5M | -$8.9M | -$6.7M |
| Gross margin | — | — | — |
| Operating margin | -2563.5% | — | — |
| Net margin | -2909.1% | — | — |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | -$1.3M | -$1.6M | -$2.0M | -$2.0M | -$2.5M | -$2.5M | -$2.7M | -$2.4M |
| Net income | -$1.4M | -$1.7M | -$1.8M | -$1.9M | -$2.4M | -$2.3M | -$2.7M | -$2.4M |
| Diluted EPS | -$0.22 | -$0.27 | -$0.24 | -$0.22 | -$0.28 | -$0.27 | -$0.32 | -$0.28 |
| Operating cash flow | -$2.5M | -$541,524.00 | -$5.7M | -$1.1M | -$1.5M | -$1.9M | -$2.0M | -$1.5M |
| Free cash flow | -$2.6M | -$541,524.00 | -$5.9M | -$1.2M | -$1.6M | -$1.9M | -$2.0M | -$1.6M |
| Gross margin | — | — | — | — | — | — | — | — |
| Operating margin | — | — | — | — | — | — | — | — |
| Net margin | — | — | — | — | — | — | — | — |
Company news
Jun 30, 2026
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-04-09 | Korman Tyler Paz· Chief Scientific Officer | Sale | 750 | $10.53 | $7,893.75 | filing |
| 2026-04-08 | Korman Tyler Paz· Chief Scientific Officer | Sale | 750 | $10.04 | $7,530.45 | filing |
| 2026-04-01 | Perriman Damien Alan· Chief Commercial Officer | Award | 8,887 | $8.44 | $75,006.28 | filing |
| 2026-04-01 | Nawaz Fouad· Vice President- Finance | Award | 5,999 | $8.44 | $50,631.56 | filing |
| 2026-04-01 | Korman Tyler Paz· Chief Scientific Officer | Award | 5,332 | $8.44 | $45,002.08 | filing |
| 2026-04-01 | Opgenorth Paul Hideo· Vice President, Development | Award | 3,999 | $8.44 | $33,751.56 | filing |
| 2026-04-01 | Perriman Damien Alan· Chief Commercial Officer | Award | 62,759 | $0.00 | $0.00 | filing |
| 2025-07-02 | Heltzen Michael· Chief Executive Officer | Buy | 1,040 | $10.22 | $10,628.80 | filing |
| 2025-06-16 | Korman Tyler Paz· Vice President, Research | Award | 2,990 | $12.54 | $37,494.60 | filing |
Latest 9 transactions.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.